Director, ADC & MSAT

About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small‑molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first‑in‑class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody‑drug conjugates (ADCs) for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. Location South San Francisco, CA. Position Summary We are seeking a Director, ADC MSAT to manage development, technology transfer, manufacturing, and BLA/launch preparation activities at CDMOs for IDEAYA’s antibody‑drug conjugate (ADC) platform and pipeline. This role will be an integral part of a team built to execute the CMC strategy required to advance ADC programs through clinical development and to enable global commercial launch and post‑approval supply. The position requires a seasoned Development/MSAT professional with technical experience in antibody/ADC development and a strong execution capability across clinical and commercial stages. The successful candidate will operate within a predominantly outsourced manufacturing model while supporting the development of scalable internal capabilities. This position is based in our South San Francisco headquarters and requires onsite presence four days per week in accordance with company policy. Reporting To Vice President, Antibody Drug Conjugate (ADC) Development and Manufacturing. #J-18808-Ljbffr Initial Therapeutics, Inc.